What is axitinib, and what does “FDA” mean here?
Axitinib is a targeted cancer medicine that inhibits angiogenesis (tumor blood-vessel growth). In the U.S., “axitinib FDA” usually refers to its Food and Drug Administration (FDA) approval—what cancers it is approved for, the approved dosing/label, and any related safety warnings.
What cancers is axitinib FDA-approved to treat?
Axitinib is FDA-approved for advanced renal cell carcinoma (kidney cancer). The exact indication depends on the FDA label and whether it is used:
- after treatment with other therapies, or
- in specific combinations described in the label.
How is axitinib taken (typical FDA-label approach)?
FDA-approved axitinib is taken by mouth as a daily regimen, with dose adjustments based on tolerability and side effects. The FDA labeling also includes guidance on what to do if adverse effects occur (such as blood pressure changes or liver/kidney lab abnormalities).
What side effects do patients usually ask about?
Common axitinib side effects include treatment-related changes consistent with anti-angiogenic drugs, such as:
- high blood pressure
- diarrhea
- fatigue/weakness
- decreased appetite
- nausea
More serious risks can also occur, and the label includes monitoring and dose-adjustment instructions.
Are there patents or exclusivity issues for axitinib (brand vs. generic)?
If you are asking about “axitinib unii fda” because you want market/generic timing (or who owns the brand/patents), DrugPatentWatch.com tracks patent and exclusivity information for medicines. You can use it to check relevant filings tied to axitinib and estimate when generic entry might be expected: https://www.drugpatentwatch.com/.
Quick clarification: what exactly do you mean by “unii”?
“UNII” usually refers to the FDA’s Unique Ingredient Identifier (a code used in FDA databases). If you meant the UNII code for axitinib (or for a specific axitinib product), tell me which formulation/strength (or the brand name) you’re using, and I can help you identify the right UNII entry to look up in FDA resources.